Fenspiride

Fenspiride

SCHEMBL17006239

O=C1NCC2(CCN(CCc3ccccc3)CC2)O1.[Cl-].[H+]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Fenspiride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHRM2 known ✓ P08172 1/20 0.97
LMNA P02545 1/20 0.97
ADRA2A P08913 1/20 0.97
CYP2D6 P10635 1/20 0.97
TSHR P16473 1/20 0.97
DRD1 P21728 1/20 0.97
MAPT P10636 1/20 0.95
KMT2A Q03164 1/20 0.95
SIGMAR1 Q99720 15/20 0.58
OPRM1 P35372 10/20 0.58
DRD2 P14416 4/20 0.56
HTR2A P28223 1/20 0.55
KCNH2 Q12809 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenspiride SCHEMBL21016 0.99 LMNA (1.00) LMNACHRM2ADRA2ACYP2D6TSHR
Fenspiride SCHEMBL613462 0.97 MAPT (1.00) LMNACHRM2ADRA2ACYP2D6TSHR
Fenspiride SCHEMBL9223216 0.97 LMNA (0.97) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL9068521 0.85 LMNA (0.75) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL2604320 0.85 TSHR (0.75) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL11285193 0.82 LMNA (0.70) LMNACHRM2ADRA2ACYP2D6TSHR
Hydrochloric Acid SCHEMBL11284963 0.81 MAPT (0.71) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL17317198 0.81 LMNA (0.69) LMNACHRM2ADRA2ACYP2D6TSHR
Fenspiride SCHEMBL6671915 0.81 LMNA (0.67) LMNACHRM2ADRA2ACYP2D6TSHR
SCHEMBL17101331 0.80 TSHR (0.68) LMNACHRM2ADRA2ACYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230082555-A1 Composition for Medium KATAOKA CORPORATION (JP) 2023-03-16 US disclosed
EP-4083194-A1 COMPOSITION FOR MEDIUM Kataoka Corporation (JP) 2022-11-02 EP disclosed
CN-114729312-A Composition for culture medium 株式会社片冈制作所 2022-07-08 CN disclosed
WO-2021106698-A1 COMPOSITION FOR MEDIUM 株式会社片岡製作所 2021-06-03 WO disclosed
EP-3482753-B1 COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL PHARNEXT (FR) 2021-01-27 EP disclosed
US-20200222409-A1 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL PHARNEXT (FR) 2020-07-16 US disclosed
US-10617689-B2 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level PHARNEXT (FR) 2020-04-14 US disclosed
US-10596160-B2 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level PHARNEXT (FR) 2020-03-24 US disclosed
EP-2914252-B1 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL PHARNEXT (FR) 2019-09-04 EP disclosed
EP-3482753-A1 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL Pharnext (FR) 2019-05-15 EP disclosed
US-20190008841-A1 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL PHARNEXT (FR) 2019-01-10 US disclosed
US-10092554-B2 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level PHARNEXT (FR) 2018-10-09 US disclosed
EP-3137065-A2 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES Pharnext (FR) 2017-03-08 EP disclosed
US-20170049777-A1 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES PHARNEXT (FR) 2017-02-23 US disclosed
US-20160235693-A1 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL PHARNEXT (FR) 2016-08-18 US disclosed
WO-2015165948-A2 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES PHARNEXT (FR) 2015-11-05 WO disclosed
US-20150231123-A1 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL PHARNEXT (FR) 2015-08-20 US disclosed